Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Challenges and approaches for the development of safer immunomodulatory biologics.
Sathish JG, Sethu S, Bielsky MC, de Haan L, French NS, Govindappa K, Green J, Griffiths CE, Holgate S, Jones D, Kimber I, Moggs J, Naisbitt DJ, Pirmohamed M, Reichmann G, Sims J, Subramanyam M, Todd MD, Van Der Laan JW, Weaver RJ, Park BK. Sathish JG, et al. Among authors: moggs j. Nat Rev Drug Discov. 2013 Apr;12(4):306-24. doi: 10.1038/nrd3974. Nat Rev Drug Discov. 2013. PMID: 23535934 Free PMC article. Review.
Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment.
Tessier Y, Achanzar W, Mihalcik L, Amuzie C, Andersson P, Parry JD, Moggs J, Whiteley LO. Tessier Y, et al. Among authors: moggs j. Nucleic Acid Ther. 2021 Feb;31(1):7-20. doi: 10.1089/nat.2020.0892. Epub 2020 Oct 15. Nucleic Acid Ther. 2021. PMID: 33054599
Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
Reynolds VL, Butler P, Abernathy MM, Aschenbrenner L, Best DD, Blank J, Crosby M, Custer L, Escobar PA, Kolaja K, Moggs J, Shuey D, Snyder C, Van Vleet T, Zhou J, Hart TK. Reynolds VL, et al. Among authors: moggs j. Regul Toxicol Pharmacol. 2020 Nov;117:104746. doi: 10.1016/j.yrtph.2020.104746. Epub 2020 Sep 8. Regul Toxicol Pharmacol. 2020. PMID: 32911461
Investigative safety science as a competitive advantage for Pharma.
Moggs J, Moulin P, Pognan F, Brees D, Leonard M, Busch S, Cordier A, Heard DJ, Kammüller M, Merz M, Bouchard P, Chibout SD. Moggs J, et al. Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1071-82. doi: 10.1517/17425255.2012.693914. Epub 2012 Jul 7. Expert Opin Drug Metab Toxicol. 2012. PMID: 22769724 Review.
Using human genetics to improve safety assessment of therapeutics.
Carss KJ, Deaton AM, Del Rio-Espinola A, Diogo D, Fielden M, Kulkarni DA, Moggs J, Newham P, Nelson MR, Sistare FD, Ward LD, Yuan J. Carss KJ, et al. Among authors: moggs j. Nat Rev Drug Discov. 2023 Feb;22(2):145-162. doi: 10.1038/s41573-022-00561-w. Epub 2022 Oct 19. Nat Rev Drug Discov. 2023. PMID: 36261593 Review.
Translational Safety Genetics.
Bhoumik P, Del Rio-Espinola A, Hahne F, Moggs J, Grenet O. Bhoumik P, et al. Among authors: moggs j. Toxicol Pathol. 2017 Jan;45(1):119-126. doi: 10.1177/0192623316675064. Epub 2016 Dec 8. Toxicol Pathol. 2017. PMID: 27932582 Review.
Circulating microRNAs as potential markers of human drug-induced liver injury.
Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Moggs J, Goldring CE, Park BK. Starkey Lewis PJ, et al. Among authors: moggs j. Hepatology. 2011 Nov;54(5):1767-76. doi: 10.1002/hep.24538. Hepatology. 2011. PMID: 22045675 Clinical Trial.
Serum microRNA biomarkers for drug-induced liver injury.
Starkey Lewis PJ, Merz M, Couttet P, Grenet O, Dear J, Antoine DJ, Goldring C, Park BK, Moggs JG. Starkey Lewis PJ, et al. Among authors: moggs jg. Clin Pharmacol Ther. 2012 Sep;92(3):291-3. doi: 10.1038/clpt.2012.101. Epub 2012 Jul 25. Clin Pharmacol Ther. 2012. PMID: 22828715 Review.
81 results